A PROSPECTIVE PHASE II STUDY OF INDUCTION ERLOTINIB THERAPY IN STAGE IIIA-N2 NON-SMALL-CELL LUNG CANCER

被引：0
|
作者：
Zhong, W. -Z.
Yang, X. -N.
Liao, R. -Q.
Nie, Q.
Su, J.
Zhang, X. -C.
An, S. -J.
Zhou, Q.
Yang, J. -J.
Wu, Y. -L.
机构：
[1] Guangdong Gen Hosp, Guangdong Lung Canc Inst, Guangzhou, Guangdong, Peoples R China
[2] Guangdong Acad Med Sci, Guangzhou, Guangdong, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：43 / 43
页数：1
相关论文
共 50 条
  • [31] Tumor Mutation Load: A Novel Independent Prognostic Factor in Stage IIIA-N2 Non-Small-Cell Lung Cancer
    Kang, Jingjing
    Luo, Yang
    Wang, Di
    Men, Yu
    Wang, Jianyang
    Che, Yi-Qun
    Hui, Zhouguang
    DISEASE MARKERS, 2019, 2019
  • [32] Risk Associated with Bilobectomy after Neoadjuvant Concurrent Chemoradiotherapy for Stage IIIA-N2 Non-small-cell Lung Cancer
    Cho, Jong Ho
    Kim, Jhingook
    Kim, Kwhanmien
    Shim, Young Mog
    Kim, Hong Kwan
    Choi, Yong Soo
    WORLD JOURNAL OF SURGERY, 2012, 36 (05) : 1199 - 1205
  • [33] Induction Chemoradiotherapy (50 Gy), Followed by Resection, for Stage IIIA-N2 Non-Small Cell Lung Cancer
    Tanaka, Fumihiro
    Yokomise, Hiroyasu
    Soejima, Toshinori
    Uramoto, Hidetaka
    Yamanaka, Takeharu
    Nakagawa, Kazuhiko
    Yamamoto, Nobuyuki
    Nishimura, Yasumasa
    Niwa, Hiroshi
    Okada, Morihito
    Nakagawa, Tatsuo
    Yamashita, Motohiro
    ANNALS OF THORACIC SURGERY, 2018, 106 (04): : 1018 - 1024
  • [34] Role of adjuvant therapy in resected stage II/IIIA non-small-cell lung cancer
    Movsas, B
    ONCOLOGY-NEW YORK, 2002, 16 (01): : 90 - +
  • [35] Final Results of Prospective Phase II Study of Adding Erlotinib to Chemoradiation for patients with Stage III Non-Small-Cell Lung Cancer
    Komaki, Ritsuko
    Allen, Pamela
    Wei, Xiong
    Blumenschein, George
    Tang, Xi Ming
    Lee, J.
    Welsh, James
    Wistuba, Ignacio
    Liu, Diane
    Meyn, Ray
    Hong, Waun
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S870 - S870
  • [36] Case Report: Neoadjuvant and Adjuvant Crizotinib Targeted Therapy in Stage IIIA-N2 ALK-Positive Non-Small-Cell Lung Cancer
    Xie, Xiao-Hong
    Zhan, Ze-Jiang
    Qin, Yin-Yin
    Jiang, Ju-Hong
    Yin, Wei-Qiang
    Zheng, Rong-Hui
    Li, Shi-Yue
    Zhou, Cheng-Zhi
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [37] Erlotinib as Neoadjuvant Therapy in Stage IIIA (N2) EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Prospective, Single-Arm, Phase II Study
    Xiong, Liwen
    Li, Rong
    Sun, Jiayuan
    Lou, Yuqing
    Zhang, Weiyan
    Bai, Hao
    Wang, Huiming
    Shen, Jie
    Jing, Bo
    Shi, Chunlei
    Zhong, Hua
    Gu, Aiqin
    Jiang, Liyan
    Shi, Jianxing
    Fang, Wentao
    Zhao, Heng
    Zhang, Jie
    Wang, Junyuan
    Ye, Junyi
    Han, Baohui
    ONCOLOGIST, 2019, 24 (02): : 157 - +
  • [38] Re: Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer - Response
    Van Schil, P.
    Van Meerbeeck, J.
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2007, 99 (15) : 1210 - 1211
  • [39] Potential use of FDG-PET scan after induction chemotherapy in surgically staged IIIa-N2 non-small-cell lung cancer:: A prospective pilot study
    Vansteenkiste, JF
    Stroobants, SG
    De Leyn, PR
    Dupont, PJ
    Verbeken, EK
    ANNALS OF ONCOLOGY, 1998, 9 (11) : 1193 - 1198
  • [40] Postoperative Radiotherapy for Resected Stage IIIA-N2 Non-small-cell Lung Cancer: A Population-Based Time-Trend Study
    Zeng, Wan-Qin
    Feng, Wen
    Xie, Li
    Zhang, Chen-Chen
    Yu, Wen
    Cai, Xu-Wei
    Fu, Xiao-Long
    LUNG, 2019, 197 (06) : 741 - 751
12345